Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma (FIDES-03)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04604132 |
|
Recruitment Status :
Terminated
(Terminated prematurely for administrative reasons not related to patient safety.)
First Posted : October 27, 2020
Last Update Posted : February 16, 2023
|
Sponsor:
Basilea Pharmaceutica
Information provided by (Responsible Party):
Basilea Pharmaceutica
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Terminated |
|---|---|
| Actual Primary Completion Date : | December 29, 2022 |
| Actual Study Completion Date : | December 29, 2022 |